An Overview of PARP Inhibitors for the Treatment of Breast Cancer Laura CortesiHope S. RugoChristian Jackisch Review Article Open access 12 March 2021 Pages: 255 - 282
Coming of Age of Immunotherapy of Urothelial Cancer Enrique GrandeJavier Molina-CerrilloAndrea Necchi Review Article 12 March 2021 Pages: 283 - 294
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives Javier MunozGeorge A. FollowsLoretta J. Nastoupil Review Article Open access 09 March 2021 Pages: 295 - 308
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA Giorgio PatelliCaterina VaghiAndrea Sartore-Bianchi Review Article Open access 18 March 2021 Pages: 309 - 324
Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy Oluwaseun O. AkinduroPaola Suarez-MeadeAlfredo Quiñones-Hinojosa Systematic Review 24 April 2021 Pages: 325 - 337
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C Kiyotaka YohTomonori HirashimaGeoffrey R. Oxnard Original Research Article Open access 03 May 2021 Pages: 339 - 355
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry Anders BjartellNicolaas LumenSimon Chowdhury Original Research Article Open access 07 April 2021 Pages: 357 - 367
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer Danielle MeyrickMarat GallyamovNat Lenzo Original Research Article 09 March 2021 Pages: 369 - 380
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program Thomas AparicioNathalie CozicGilles Vassal Original Research Article Open access 13 April 2021 Pages: 381 - 388
TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting Lyudmila BazhenovaAndrew LokkerXiaolong Jiao Original Research Article Open access 24 April 2021 Pages: 389 - 399
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis Yeonghak BangChanghoon YooAndrea Casadei-Gardini Original Research Article 01 March 2021 Pages: 401 - 410
Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis Yeonghak BangChanghoon YooAndrea Casadei-Gardini Correction 18 March 2021 Pages: 411 - 412
Correction to: Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA Giorgio PatelliCaterina VaghiAndrea Sartore-Bianchi Correction 31 March 2021 Pages: 413 - 413